¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Purified Hepatitis B Surface Antigen Protein"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
¿µ¹® acute hepatitis ÇÑ±Û ±Þ¼º°£¿°
¼³¸í   
  ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ °£¿¡ »ý±â´Â ±Þ¼º¿°Áõ. ±Þ¼º°£¿°À̶õ °£¿°¹ÙÀÌ·¯½º(AÇü-BÇü-ºñAºñBÇü)¿¡ ÀÇÇØ¼­ °£¿¡ »ý±â´Â ±Þ¼º¿°ÁõÀ» º´¸íÀ¸·Î À̸£´Â ¸»·Î, À̴ ±× °¨¿°¾ç½Ä¿¡ ¼öÇ÷ ÈÄ¿¡ ¹ß»ýÇϴ ¼öÇ÷ÈÄ °£¿°°ú, °¨¿°°æ·Î¸¦ ¾Ë ¼ö ¾ø´Â »ê¹ß¼º°£¿° ¹× Áý´ÜÀ¸·Î ¹ß»ýÇϴ À¯Ç༱°£¿°ÀÇ ¼¼°¡Áö À¯ÇüÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù. ¼öÇ÷ÈÄ °£¿°Àº ±× 95%°¡ ºñAºñBÇü°£¿°À̸砳ª¸ÓÁö°¡ BÇü °£¿°ÀÌ´Ù. »ê¹ß¼º °£¿°Àº AÇü °£¿°°ú BÇü °£¿°ÀÌ °¢°¢ 30%¸¦ ÀÌ·ç°í ³ª¸ÓÁö 40%´Â ºñAºñB°£¿°ÀÌ´Ù. Áý´ÜÀ¸·Î ¹ß»ýÇϴ À¯Ç༺°£¿°Àº °ÅÀǰ¡ AÇü°£¿°ÀÌÁö¸¸ ¶§·Î´Â ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾ÊÀº ÇüÀÇ °£¿°ÀÏ °æ¿ìµµ ÀÖ´Ù. ±Þ¼º°£¿°ÀÇ Áõ¼¼´Â ¸ÕÀú ¸öÀÌ ³ª¸¥ÇØÁö°í ¿Â¸ö¿¡ ±ÇۨÀ̠ã¾Æ¿À¸ç Á¶±×¸¶ÇÑ ÀÏ¿¡µµ °ð ÇǷθ¦ ´À³¢°Ô µÈ´Ù. ±×¸®°í ½Ä¿åºÎÁø-¹ß¿­-±¸ÅäÁõ-º¹Åë-¼³»ç µî, °¨±â³ª ±Þ¼ºÀ§Àå¿°¿¡ °É·ÈÀ» ¶§¿Í °°Àº Áõ¼¼ µîÀÌ ³ªÅ¸³­´Ù. µÚÀ̾î È²´ÞÁõ¼¼¸¦ º¸À̴µ¥, À̶§´Â ÃʱâÀÇ Áõ¼¼°¡ ¾à°£ °¡º­¿öÁø °Íó·³ ´À²¸Áö´Â °ÍÀÌ º¸ÅëÀÌ´Ù. ±×·¯³ª È²´ÞÁõ¼¼°¡ ½ÉÇØÁö°í ÃʱâÀÇ Áõ¼¼µéÀÌ ´Ù½Ã ÁøÇàµÇ¸é À̶§´Â Àü°Ý¼º°£¿°ÀÌ µÉ À§ÇèÀÌ ÀÖ´Ù. °£¿° Áõ¼¼°¡ ½ÉÇÏÁö ¾Ê¾ÒÀ» °æ¿ì´Â È²´ÞÀÌ ´«¿¡ ¶çÁö ¾ÊÀº °æ¿ìµµ Àִµ¥ À̶§´Â ÁøÂûÀ» Çصµ °¨±â³ª ±Þ¼ºÀ§Ã¢ÀÚ¿°À¸·Î ÀÚÄ© ¿ÀÁøµÇ±â ½±´Ù. ¶Ç AÇü°£¿°Àº ¿­ÀÌ 38~39¡É±îÁö ¿À¸£°í Áõ¼¼°¡ °©Àڱ⠳ªÅ¸³ª´Â °ÍÀ̠Ư¡À̸砱޼ººñAºñBÇü°£¿°Àº Áõ¼¼°¡ ºñ±³Àû °¡º­¿î °ÍÀ̠Ư¡ÀÌ´Ù. ±Þ¼ºBÇü°£¿°ÀÇ Áõ¼¼´Â AÇü°£¿°°ú ±Þ¼ººñAºñBÇü°£¿°ÀÇ Áß°£ Á¤µµÀΠ°ÍÀÌ º¸ÅëÀÌ´Ù.
¿µ¹® chronic active hepatitis ÇÑ±Û ¸¸¼ºÈ°µ¿°£¿°
¼³¸í   
  BÇü °£¿°À̳ª ºñAÇü£­ºñBÇü °£¿°ÀÇ ¼Ó¹ßÁõÀ¸·Î ³ªÅ¸³ª´Â °£ÀÇ ¸¸¼º¿°ÁõÀÌ´Ù. °°Àº ÇüÅÂÀÇ º´ÀÌ ¼±Ãµ¼º ¶Ç´Â ÈÄõ°¨¸¶±Û·ÎºÒ¸°°áÇÌÁõÀ̳ª ¾î¶² Á¾·ùÀÇ ¾à¹° Åõ¿©¿¡ ¼ö¹ÝÇØ¼­ ³ªÅ¸³¯ ¼öµµ ÀÖ´Ù. Æ¯Â¡ÀûÀ¸·Î ¹®¸ÆºÎ¿¡ ÇüÁú¼¼Æ÷¿Í Å«Æ÷½Ä¼¼Æ÷ÀǠħÀ±, Á¶°¢±«»ç(°£¼Ò¿± ÁÖº¯ºÎ °£¼¼Æ÷ÀÇ ÆÄ±«) ¹× ¼¶À¯Áõ µîÀÇ Á¶Á÷¼Ò°ßÀ» ³ªÅ¸³½´Ù. º´ÀÇ °æ°ú´Â ¸Å¿ì ´Ù¾çÇϸç Àå±â°£ÀÇ ¹«Áõ»ó±â¸¦ º¸ÀÏ ¼öµµ ÀÖ°í ±× »çÀÌ »çÀÌ¿¡ È²´Þ, Àü½Å¼è¾à, ½Ä¿åºÎÁø ¹× ¹ß¿­ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼ö°¡ ÀÖÀ¸¸ç, ¶Ç ¹«¿ù°æÁõ, °üÀý¿°, ÇǺιßÁø, Ç÷°ü¿°, °©»ó»ù¿°, ÄáÆÏ»ç±¸Ã¼¿°, ±Ë¾ç¼º´ëÀå¿°, ½¦±×·»ÁõÈıº µî °£ ÀÌ¿ÜÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼öµµ ÀÖ°í, °£°æÈ­Áõ°ú °£±â´É»ó½Ç·Î ÁøÇàµÇ´Â ¼öµµ ÀÖ´Ù. ÀÚ°¡¸é¿ª¸ÞÄ¿´ÏÁòÀÌ °ü¿©µÇ´Â °ÍÀ¸·Î ÃßÃøµÇ°í ÀÖ´Ù.
¿µ¹® fulminant hepatitis ÇÑ±Û Àü°Ý°£¿°
¼³¸í   
  ¹ÙÀÌ·¯½º °£¿°ÀÇ ÇÑ ÇüÀ¸·Î ±Þ¼º È²»öÀ§ÃàÁõÀ̶ó°íµµ ºÎ¸¥´Ù. °£¼¼Æ÷ÀÇ ´ëºÎºÐÀÌ ±«»ç»óÅ·ΠµÇ¸ç È¯Àڴ º¸Åë »ç¸ÁÇÑ´Ù. È²´ÞÀÌ ³ªÅ¸³ª±â ÀüºÎÅÍ À̹̠Áõ»óÀº ÇöÀúÈ÷ ÁøÇàÇÏ¿© È²´ÞÀÇ ÃâÇöµµ ºü¸£°í, ±Þ¼º ¹ß¿­À» ¼ö¹ÝÇϸç Á¡¸·À̳ª ÇÇÇÏÃâÇ÷À» º¼ ¼ö ÀÖ´Ù. °£ÀÇ ¾ÐÅëÀ» ¼ö¹ÝÇϴ ¼öµµ ÀÖ´Ù. À§Ãà¿¡ ÀÇÇÏ¿© °£Àº ÀÚÁÖ ÀÛ¾ÆÁø´Ù. ÃÖÈÄ¿¡´Â ÀǽÄÀå¾Ö¸¦ ÃÊ·¡ÇÏ¿© Á¹À½ÀÌ ¿À°í È¥¹Ì»óÅ·ΠµÇ¸ç °£¼ºÈ¥¼ö·Î ÁøÇàÇÏ¿© »ç¸ÁÇϰԠµÈ´Ù. Áõ»óÀÌ ½ÃÀ۵Ǿî 2~3ÁÖ ³»¿¡ °£³úº´Áõ±îÁö ÁøÇàÇϴ °£±â´É »ó½ÇÀ» Àü°Ý¼º °£±â´É»ó½ÇÀ̶ó°í ºÎ¸£¸ç, ÁøÇà ¼Óµµ°¡ ºü¸£Áö ¾Ê¾Æ¼­ 3°³¿ù¿¡ À̸£·¯ °£±â´É»ó½Ç¿¡ ºüÁö´Â °ÍÀº ¾Æ±Þ¼º °£±â´É»ó½ÇÀ̶ó°í ºÎ¸¥´Ù. ¸ðµç °£¿° ¹ÙÀÌ·¯½º°¡ ¸ðµÎ ÀÏÀ¸Å°Áö´Â ¾Ê´Â´Ù. °£¿°A¹ÙÀÌ·¯½º¿Í °£¿°E¹ÙÀÌ·¯½º´Â º¸À¯ÀÚ »óųª ¸¸¼º °£¿°À» °ÅÀÇ ÀÏÀ¸Å°Áö ¾Ê´Â´Ù. ±âŸ ´Ù¸¥ °¨¿° ¶Ç´Â ºñ°¨¿°¼º ¿øÀÎ, Æ¯È÷ ¾à¹°°ú µ¶¼Òµµ º»ÁúÀûÀ¸·Î µ¿ÀÏÇÑ ÁõÈĸ¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. ±×·¯¹Ç·Î ¹ÙÀÌ·¯½º¼º °£¿°ÀÇ Áø´Ü°ú °¢ °£¿° ¹ÙÀÌ·¯½º¸¦ ±¸º°Çϴµ¥´Â Ç÷ûÇÐÀû °Ë»ç°¡ ÇʼöÀûÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chronic persistent hepatitis
    ¸¸¼ºÁö¼Ó°£¿°
  • drug-induced hepatitis
    ¾à¹°À¯¹ß°£¿°
  • delta hepatitis
    µ¨Å¸°£¿°
  • epidemic hepatitis
    À¯Çà°£¿°
  • fulminant hepatitis
    Àü°Ý°£¿°
  • granulomatous hepatitis
    À°¾ÆÁ¾°£¿°
  • gummatous hepatitis
    °í¹«Á¾°£¿°
  • hepatitis
    °£¿°
  • hepatitis A
    AÇü°£¿°
  • hepatitis B
    BÇü°£¿°
  • hepatitis B vaccine
    BÇü°£¿°¹é½Å
  • hepatitis C
    CÇü°£¿°
  • hepatitis contagiosa canis
    °³Á¢Ã˰¨¿°°£¿°
  • hepatitis D
    DÇü°£¿°
  • hepatitis E
    EÇü°£¿°
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • surface area
    üǥ¸éÀû, Ç¥¸éÀû
  • surface coil
    Ç¥¸éÄÚÀÏ, Ç¥¸é°ËÃâ±â
  • surface characteristic
    Ç¥¸éƯ¼º
  • surface electrode
    Ç¥¸éÀü±Ø
  • surface
    Ç¥¸é, ¸é
  • articular surface
    °üÀý¸é
  • dorsal surface
    µîÂʸé, µÞ¸é
  • lateral surface
    °¡Âʸé, ¿ÜÃø¸é
  • potential surface
    ÀüÀ§¸é
  • proximate surface
    ÀÎÁ¢¸é
  • surface tension
    Ç¥¸éÀå·Â
  • antigen
    Ç׿ø
  • antigen analysis
    Ç׿øºÐ¼®
  • carcinoembryonic antigen
    ¾ÏÁ¾¹è¾ÆÇ׿ø
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • epidemic hepatitis
    À¯Ç༺°£¿°
  • fulminant hepatitis
    Àü°Ý°£¿°
  • granulomatous hepatitis
    À°¾ÆÁ¾°£¿°
  • gummatous hepatitis
    °í¹«Á¾°£¿°
  • hepatitis
    °£¿°
  • hepatitis A
    ¿¡ÀÌÇü°£¿°
  • hepatitis B
    ºñÇü°£¿°
  • hepatitis C
    ¾¾Çü°£¿°
  • hepatitis contagiosa canis
    °³Àü¿°°£¿°
  • hepatitis D
    µðÇü°£¿°
  • halothane hepatitis
    ÇÒ·Îź°£¿°
  • hepatitis carrier state
    °£¿°º¸±ÕÀÚ»óÅÂ
  • infantile hepatitis
    ¿µ¾Æ°£¿°
  • infectious hepatitis
    Àü¿°°£¿°, ¿¡ÀÌÇü°£¿°
  • lupus hepatitis
    ·çǪ½º°£¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anterior articular surface
    ¾Õ°üÀý¸é
  • anterior articular surface for talus
    ¾Õ¸ñ¸»°üÀý¸é
  • anterior calcaneal articular surface
    ¾Õ¹ß²ÞÄ¡°üÀý¸é
  • anterior surface
    ¾Õ¸é
  • anterior surface of eyelid
    ´«²¨Ç®¾Õ¸é
  • anterior surface of petrous portion
    ¹ÙÀ§¾Õ¸é
  • anterolateral surface
    ¾Õ°¡Âʸé
  • anteromedial surface
    ¾Õ¾ÈÂʸé
  • approximal surface
    Á¢Ã˸é
  • articular surface
    °üÀý ¸é(¡­Øü).
  • articular surface
    °üÀý¸é
  • articular surface for cuboid bone
    ÀÔ¹æ°üÀý¸é
  • articular surface for fibula
    Á¾¾Æ¸®°üÀý¸é
  • articular surface for navicular bone
    ¹ß¹è°üÀý¸é
  • articular surface of fibular head
    Á¾¾Æ¸®»À¸Ó¸®°üÀý¸é
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • capsular antigen =K. antigen
    Çù¸·Ç׿ø(¡­ù÷ê«).
  • acute hepatitis
    ±Þ¼º °£¿°
  • acute viral hepatitis
    ±Þ¼º¹ÙÀÌ·¯½º¼º °£¿° (~ÊÜæú)
  • acute viral hepatitis
    ±Þ¼º ¹ÙÀÌ·¯½º°£¿°(¡­ÊÜæú).
  • alcoholic hepatitis
    ¾ËÄڿüº °£¿°
  • alcoholic hepatitis
    ¾ËÄڿüº °£¿°(¡­àõÊÜæú)
  • amebic hepatitis
    ¾Æ¸Þ¹Ù¼º °£¿°
  • anicteric hepatitis
    ¹«È²´Þ¼º °£¿°.
  • autoimmune hepatitis
    ÀÚ°¡¸é¿ª¼º °£¿°
  • canine hepatitis virus
    °³°£¿°¹ÙÀÌ·¯½º
  • cholestatic hepatitis
    ´ãÁó¿ïü¼º °£¿°, ´ãÁóÁ¤Ã¼¼º °£¿°.
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿¼º °£¿°(¡­ÊÜæú).
  • chronic active hepatitis
    ¸¸¼º Ȱµ¿¼º °£¿°
  • chronic hepatitis
    ¸¸¼º °£¿°
  • chronic hepatitis
    ¸¸¼º°£¿°
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Auricular surface
    ±Í¸ð¾ç¸é
    [¿¾ ¿ë¾î] ÀÌ»ó¸é
  • Viceral surface
    ³»Àå¸é
    [¿¾ ¿ë¾î] ÀåÃø¸é
  • Visceral surface
    ³»Àå¸é
    [¿¾ ¿ë¾î] ÀåÃø¸é
  • Posterior surface of eyelids
    ´«²¨Ç®µÚ¸é
    [¿¾ ¿ë¾î] ¾È°ËÈĸé
  • Anterior surface of eyelid
    ´«²¨Ç®¾Õ¸é
    [¿¾ ¿ë¾î] ¾È°ËÀü¸é
  • Orbital surface
    ´«È®¸é
    [¿¾ ¿ë¾î] ¾È¿Í¸é
  • Cerebral surface
    ´ë³ú¸é
    [¿¾ ¿ë¾î] ´ë³ú¸é
  • Symphyseal surface
    µÎµ¢°áÇÕ¸é
    [¿¾ ¿ë¾î] Ä¡°ñ°áÇÕ¸é
  • Posterior articular surface
    µÚ°üÀý¸é
    [¿¾ ¿ë¾î] ÈİüÀý¸é
  • Dorsal surface
    µÚ¸é
    [¿¾ ¿ë¾î] Èĸé
  • Intestinal surface
    µÚ¸é
    [¿¾ ¿ë¾î] Èĸé
  • Posterior surface
    µÚ¸é
    [¿¾ ¿ë¾î] Èĸé
  • Posterior articular surface for talus
    µÚ¸ñ¸»°üÀý¸é
    [¿¾ ¿ë¾î] ÈİŰñ°üÀý¸é
  • Posterior calcaneal articular surface
    µÚ¹ß²ÞÄ¡°üÀý¸é
    [¿¾ ¿ë¾î] ÈÄÁ¾°ñ°üÀý¸é
  • Dorsal surface
    µî¸é
    [¿¾ ¿ë¾î] ¹èÃø¸é
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • surface potential
    Ç¥¸éÀüÀ§ (øúØüï³êÈ)
  • surface pressure
    Ç¥¸é¾Ð (øúØüäâ)
  • surface tension
    Ç¥¸éÀå·Â (øúØüíåÕô)
  • van der Waals surface
    ¹Ý µ§ ¹ß½º Ç¥¸é (øúØü)
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen binding capacity
    Ç׿ø °áÇÕ´É(ù÷ê«Ì¿ùêÒö)
  • antigen binding site
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê)ÀÚ¸®
  • antigen presenting cell
    Ç׿øº¸À¯¼¼Æ÷(ù÷ê«ÜÁêóá¬øà)
  • antigen-antibody complex
    Ç׿øÇ×ü º¹ÇÕü(ù÷ê«ù÷ô÷ ÜÜùêô÷)
  • antigen-antibody lattice
    Ç׿øÇ×ü °ÝÀÚ(ù÷ê«ù÷ô÷ Ì«í­)
  • antigen-antibody reaction
    Ç׿øÇ×ü ¹ÝÀÀ(ù÷ê«ù÷ô÷Úãëë)
  • antigen-binding fragment
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê) Á¶°¢
  • antigen-excess zone
    Ç׿ø°úÀ× ±¸¿ª(ù÷ê«Î¦í¥Ï¡æ´)
  • Australia antigen
    ¿À½ºÆ®¶ö¸®¾Æ Ç׿ø (ù÷ê«)
  • Boivin antigen
    º¸¿Í¹æ Ç׿ø(ù÷ê«)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • protein metabolism
    ´Ü¹é(Áú)´ë»ç
  • protein-losing enteropathy
    ´Ü¹é»ó½Ç¼ºÀ庴Áõ
  • protein-losing gastroenteropathy
    ´Ü¹é»ó½Ç¼ºÀ§ÀåÁõ
  • serum protein
    Ç÷û´Ü¹é
  • depth resolved surface coil spectroscopy [=DRESS]
    ±íÀÌÇØ°áÇ¥¸éÄÚÀϺб¤¹ý
  • free surface
    ÀÚÀ¯¸é
  • malleolar articular surface
    ³»°ú°üÀý¸é, ³»Ãøº¹»ç°üÀý¸é
  • medial surface
    ³»Ãø¸é
  • outer surface
    ¿ÜÃøÇ¥¸é
  • quadrature surface coil
    ±¸ÀûÇ¥¸éÄÚÀÏ
  • shade surface display
    ±×¸²ÀÚÇ¥¸éÇ¥½Ã
  • smooth surface
    ÆòȰ¸é
  • SSD [=shade surface display]
    ±×¸²ÀÚÇ¥¸éÇ¥½Ã
  • surface
    Ç¥¸é
  • surface coil
    Ç¥¸éÄÚÀÏ, Ç¥¸é°ËÃâ±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ESA Electrolysis Society of America; endocardial surface area; epidermal surface antigen; esterase; este...
SA salicylic acid; saline [solution]; salt added; sarcoidosis; sarcoma; scalenus anticus; secondary ame...
HLA histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod...
¥áHBs Antibody against Hepatitis B surface Antigen
HBsAg Hepatitis B surface Antigen
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
r-HBsAg recombinant hepatitis B surface antigen
PPD Purified Protein Derivate
PPD Purified Protein Derivative
PPD Purified Protein Derivative of Tuberculin
32P Purified
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • viral hepatitis
    ¹ÙÀÌ·¯½º °£¿°, ¹ÙÀÌ·¯½º¼º °£¿°
    ÃÖ¼Ò 5Á¾ÀÇ ¼­·Î ´Ù¸¥ ¹ÙÀÌ·¯½º°¡ ¿øÀÎÀÌ µÇ¸ç ÀÌµé ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î ÀÎÇÑ °£¿°.
  • abnormal protein
    ºñÁ¤»ó ´Ü¹éÁú
  • activated protein C resistance
    Ȱ¼ºÈ­ C ´Ü¹é ³»¼º
  • acute phase protein
    ±Þ¼º±â ´Ü¹éÁú
    °¨¿°À̳ª Á¶Á÷ ¼Õ»óÀÌ ÀÖÀ» ¶§ Á¤»óº¸´Ù 2-100¹è Á¤µµ Áõ°¡ÇÏ´Â Ç÷Àå ´Ü¹éÁúÀ» ÃÑĪÇÏ¿© APP¶ó°í ÇÏ¸ç ¼±Ãµ¼º ¸é¿ª¿¡ °ü¿©ÇÑ´Ù.
  • androgen binding protein
    ³²¼º È£¸£¸ó °áÇÕ ´Ü¹é
  • bacterio protein
    ¼¼±Õ ´Ü¹éÁú
  • body protein
    ü´Ü¹é, ü´Ü¹éÁú
  • C-reactive protein
    C-¹ÝÀÀ ´Ü¹é, C-¹ÝÀÀ¼º ´Ü¹éÁú
  • cellular retinoid acid-binding protein
    ¼¼Æ÷³» ·¹Æ¼³ëÀ̵å»ê °áÇÕ ´Ü¹é
  • chromatographic protein separation
    Å©·Î¸¶Åä±×·¡Çǹý ´Ü¹é ºÐ¸®
  • D-myeloma protein
    D-°ñ¼öÁ¾ ´Ü¹é
    ¸é¿ª ±Û·ÎºÎ¸°ÀÇ ÇÑ ºÎ·ùÀÎ IgD¸¦ »ý»êÇÏ´Â °ñ¼öÁ¾¿¡¼­ ¸¸µé¾îÁø ´Ü¹éÁú.
  • eosinophil protein X
    È£»ê±¸ ´Ü¹é X
  • estrogen receptor protein
    ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ´Ü¹éÁú
  • hapten-protein conjugate
    ÇÕÅÙ ´Ü¹é °áÇÕ¹°
  • heat-aggregated protein
    ¿­ ÀÀÁý ´Ü¹é
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
autoimmune hepatitis <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver.
Symptoms are those of chronic active hepatitis.
(27 Sep 1997)
vaccination, hepatitis a When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
vaccination, hepatitis b Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. Vaccination, hepatitis b: hepatits b (hep b) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
vaccination, infectious hepatitis See Vaccination, hepatitis a.
(12 Dec 1998)
vaccineation, serum hepatitis See Vaccination, hepatitis b.
(12 Dec 1998)
giant cell hepatitis Hepatitis in the neonatal period presumed to be due to a variety of causes, chiefly viral; characterised by direct and indirect bilirubinaemia, hepatocellular degeneration, and appearance of multinucleated giant cells; may be difficult to distinguish from biliary atresia, but is more likely to end with recovery, although cirrhosis may develop.
Synonym: giant cell hepatitis.
(05 Mar 2000)
viral hepatitis Liver inflammation caused by viruses. Specific hepatitis viruses have been labelled a, b, c, d, e, f, and g. While other viruses can also cause hepatitis, their primary target is not the liver.
(12 Dec 1998)
viral hepatitis type A A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom.
Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis.
(05 Mar 2000)
viral hepatitis type B A virus disease with a long incubation period (usually 50 to 160 days), caused by hepatitis B virus, a DNA virus and member of the family Hepadnoviridae, usually transmitted by injection of infected blood or blood derivatives or by use of contaminated needles, lancets, or other instruments; clinically and pathologically similar to viral hepatitis type A, but there is no cross-protective immunity; HBsAg is found in the serum and the hepatitis delta virus occurs in some patients.
Synonym: hepatitis B, serum hepatitis, transfusion hepatitis, virus B hepatitis.
(05 Mar 2000)
viral hepatitis type C Principal cause of non-A, non-B posttransfusion hepatitis caused by an RNA virus that may be related to Flaviviridae family.
Synonym: hepatitis C, virus C hepatitis.
(05 Mar 2000)
viral hepatitis type D Acute or chronic hepatitis caused by the hepatitis delta virus, a defective RNA virus requiring HBV for replication. The acute type occurs in two forms: 1) coinfection, the simultaneous occurrence of hepatitis B virus and hepatitis delta virus infections, which usually is self-limiting; 2) superinfection, the appearance of hepatitis delta virus infection in a hepatitis B virus carrier, which often leads to chronic hepatitis The chronic type appears to be more severe than other types of viral hepatitis.
Synonym: delta hepatitis, hepatitis D.
(05 Mar 2000)
viral hepatitis type E Hepatitis caused by a nonenveloped, single-stranded, positive-sense RNA virus 27-34 nm in diameter, unrelated to other hepatitis; it is the principal cause of enterically transmitted, waterborne, epidemic NANB hepatitis occurring primarily in Asia and Africa.
Synonym: hepatitis E.
(05 Mar 2000)
viral hepatitis vaccines Any vaccine raised against any virus or viral derivative that causes hepatitis.
(12 Dec 1998)
virus A hepatitis A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom.
Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis.
(05 Mar 2000)
virus B hepatitis A virus disease with a long incubation period (usually 50 to 160 days), caused by hepatitis B virus, a DNA virus and member of the family Hepadnoviridae, usually transmitted by injection of infected blood or blood derivatives or by use of contaminated needles, lancets, or other instruments; clinically and pathologically similar to viral hepatitis type A, but there is no cross-protective immunity; HBsAg is found in the serum and the hepatitis delta virus occurs in some patients.
Synonym: hepatitis B, serum hepatitis, transfusion hepatitis, virus B hepatitis.
(05 Mar 2000)
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 4 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÇìÆÄ¹ÃÁÖ5ml - »õâ
µ¿½ÅÁ¦¾à
Purified Hepatitis B Surface Antigen Protein
Àü¹®ÀǾàǰ | ¹Ì»ý»ê
ÇìÆÄ¹ÃÁÖ10ml - »õâ
SKÄɹÌÄ®
Purified Hepatitis B Surface Antigen Protein
Àü¹®ÀǾàǰ | ¹Ì»ý»ê
ÇìÆÄ¹Ú½ºÁøÆ¼¿¡ÇÁÁÖ20§¶/ml - »õâ
³ì½ÊÀÚ¹é½Å
Purified Hepatitis B Surface Antigen Protein
Àü¹®ÀǾàǰ | ºñ±Þ¿©
À¯¹Ú½ººñÀ¯´ÏÁ§Æ®ÁÖ(BÇü°£¿°¹é½Å,À¯ÀüÀÚÀçÁ¶ÇÕ) - »õâ
LG»ý¸í°úÇÐ
Purified Hepatitis B Surface Antigen Protein, Thimerosal
Àü¹®ÀǾàǰ | ºñ±Þ¿©
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • imposing stone(table,surface)
    (ÀÎ)Á¤ÆÇ´ë
  • surface
    Ç¥¸éÀ» ºÙÀÌ´Ù;ÆÇÆÇÇÏ°Ô ÇÏ´Ù;Æ÷ÀåÇÏ´Ù
  • surface
    na;Ç¥¸é(ÀÇ);¿Ü°ü(ÀÇ);°Ñº¸±â(»ÓÀÇ);¸é
  • surface car
    ³ë¸é ÀüÂ÷
  • surface mail
    (Ç×°ø ¿ìÆí¿¡ ´ëÇÏ¿©)Áö»ó ÇØ»ó ¼ö¼Û ¿ìÆí
  • surface noise
    (·¹ÄÚµåÀÇ)¹Ù´Ã ¼Ò¸® (ÀâÀ½)
  • surface printing
    ºí·ÏÆÇ Àμâ(³¯¿°)
  • surface tension
    Ç¥¸é Àå·Â
  • surface water
    ÁöÇ¥¼ö(ÁöÇϼö¿¡ ´ëÇØ);Ç¥¸é ¼ö·®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á